Search results
Results from the WOW.Com Content Network
The Medicaid Drug Rebate Program has undergone a number of changes since its inception. For example, Section 606 of the Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act of 1999 (BBRA) amended Section 1927(a)(1) allowing states to have the option of different rebate effective dates. This section states that agreements to the rebate ...
It required pharmaceutical manufacturers to provide rebates for medication purchases, based on sales to Medicaid beneficiaries, as a condition of having their products covered by Medicaid. [3] The amount of the rebates paid to the states were based on a "best price" calculation that did not take into account the discounted prices that ...
The Medicaid drug rebate for brand name drugs, paid by drug manufacturers to the states, is increased to 23.1% (except for the rebate for clotting factors and drugs approved exclusively for pediatric use, which increases to 17.1%), and the rebate is extended to Medicaid managed care plans; the Medicaid rebate for non-innovator, multiple source ...
The report says about 44% of state residents — including 60% of those in New York City — are covered by Medicaid or the Essential Plan, seven points above any other state. The programs take up ...
The New York Times, [9] Federal Trade Commission, [27] [28] and many states' Attorneys General [12] [13] argue pharmacy benefit managers unfairly raise prices on drugs. A report by House Committee on Oversight and Accountability chairman, Kentucky Rep. James Comer , found that PBMs use utilization schemes to increase pricing for payers and ...
The 2021 recovery rebate credit is a bit different from the one issued in 2020. The third stimulus and the plus-up payments were technically advance payments of the 2021 rebate credit claimed on a ...
The IRS will send an estimated $2.4 billion to taxpayers who didn’t claim the recovery rebate credit on their 2021 tax returns. About 1 million taxpayers were eligible for the credit but failed ...
A December 2015 New York Times editorial opined that "drug prices have been pushed to astronomical heights for no reason other than the desire of drug makers to maximize profits", pointing in particular to strategies by Turing Pharmaceuticals and Valeant Pharmaceuticals for rights to make and sell generic drugs which had administrative ...